Should You Buy Rocket Lab Stock Before Its New Rocket Takes Flight?

Rocket Lab is preparing for a crucial test flight of its new Neutron rocket later this year, a development poised to significantly expand its market by competing with SpaceX in large payload launches and enabling its long-term satellite constellation plans. While the Neutron is critical for scaling Rocket Lab's operations and achieving profitability, the company's stock currently reflects an extreme valuation, trading at a 49x price-to-sales multiple based on $500 million in trailing revenue and a $24 billion market cap, suggesting that much of its future growth potential is already priced in.

Analysis

Rocket Lab (RKLB) is at a critical inflection point, with the upcoming test flight of its Neutron rocket poised to fundamentally alter its market position and financial trajectory. This new launch vehicle, with a planned payload capacity of 13,000 kilograms, is designed to compete directly with SpaceX's dominant Falcon 9, shifting Rocket Lab from a niche provider with its 300 kg payload Electron rocket into the large satellite launch market. The financial implications are significant; just ten Neutron launches at a price comparable to the Falcon 9's reported $67 million average could generate $670 million, more than doubling the company's trailing-twelve-month revenue of $500 million. Furthermore, the Neutron is the key enabler for Rocket Lab's long-term strategy to deploy its own satellite constellation and create a new services-based revenue stream. However, this substantial operational potential is challenged by an exceptionally high valuation. With a $24 billion market capitalization, the company trades at a price-to-sales (P/S) multiple of 49, indicating that significant future success is already priced into the stock. This valuation concern is compounded by a planned $750 million at-the-money stock offering to fund development, which will dilute existing shareholders.

Key Decisions for Investors

• Investors should recognize that the current 49x price-to-sales ratio presents significant valuation risk, as it implies the market has already priced in the successful and rapid commercialization of the Neutron rocket.
• The upcoming Neutron test flight is the single most important near-term catalyst; its success is critical to de-risking the investment thesis, while any delays or failures could trigger a substantial price correction.
• Factor in the near-term headwind of shareholder dilution from the planned $750 million stock offering, which, combined with the high valuation, supports a cautious stance or waiting for a more favorable entry point on a potential pullback.